After Covid, BioNTech Wants to Beat Cancer

BioNTech commences a USD 1.0 billion share repurchase program to optimize capital efficiency during its multi-product clinical pivot into oncology

8 Jun 2026

BioNTech launched a share repurchase programme of up to $1bn on 8 June, buying back American Depositary Shares on the Nasdaq through May 2027. The move comes as the German biotechnology company pivots away from respiratory vaccines and toward a broader cancer drug portfolio.

Quarterly revenue fell to 118.1 million euros, reflecting the steep drop in Covid-19 vaccine demand since the pandemic peak. The company posted a net loss of 531.9 million euros in the same period.

To cut costs, BioNTech is eliminating roughly 1,860 positions and closing manufacturing sites in Singapore and Germany. The restructuring is expected to generate 500 million euros in annual savings by 2029.

Despite the losses, the company holds 16.8 billion euros in cash, giving it room to fund its clinical ambitions without external financing. Fifteen pivotal oncology trials are scheduled to begin before December, targeting mRNA-based treatments for advanced lung and skin cancers.

The buyback is designed to return capital to shareholders while the company executes its shift toward multiple oncology products by 2030. Whether that pipeline can generate revenues at scale before cash reserves thin remains the central question for investors.